About Leucine-rich repeat-containing protein 30
Leucine-rich repeat-containing protein 30 (LRRC30) is a protein
from Homo sapiens identified by UniProt accession
A6NM36, 301 residues long.
MolForge cross-references it against 0 known binders and
51 disease associations.
Target properties
| Protein name | Leucine-rich repeat-containing protein 30 |
| UniProt accession | A6NM36 |
| Gene | LRRC30 |
| Organism | Homo sapiens |
| Length | 301 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (51)
Diseases linked to this target (Open Targets).
- obesity · score 0.23
- gut microbiome measurement · score 0.20
- bone density · score 0.19
- Blackfan-Diamond anemia · score 0.09
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome · score 0.08
- alpha thalassemia-intellectual disability syndrome type 1 · score 0.07
- Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16 · score 0.07
- delta-beta-thalassemia · score 0.06
- hemoglobin D disease · score 0.06
- hemoglobin E-beta-thalassemia syndrome · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NM36-F1 | alphafold | PREDICTED | 90.11 | — |
Amino-acid sequence (301 residues)
MGARQSRASS KDKGPKRMLF TGRRQKFSPW DDALLSGRDP RSLLKRGMHH VSFSLVTRGM TDIPDFLWGL SEVQKLNLSH NQLRVLPPEV GKLTRIVVLN LCGNRLKSLP REVSLLQCLK VLFVNMNCLT EVPAELSLCR KLEVLSLSHN CLSQLPACFA DLSRLRKLNL SNNFFAHIPM CVFSLKELIF LHVGSNRLEN IAESIQHLAS LQIFIAEGNN IHSFPRSLCL VTSLELLNLN NNDIQTLPSE LHLLCRLVRI AWNPMDKGLH ISHNPLSKPL PELVEGGLEM LFGYLKDKKH T
Explore Leucine-rich repeat-containing protein 30 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets